Skip to content
Screener

Capricor Therapeutics CAPR Financing Cash Flow

Financing Cash Flow at other companies

Pfizer logo
PfizerPFE
-$2.86B+45.4%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$241K-98.1%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$6.4M-32.0%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$324.66M+515,229%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$7.06M-95.0%
Cytokinetics logo
CytokineticsCYTK
$792.86M+910%

Other financials

Income statement

See full
Revenue--100%
Operating income-$36.8M-47.2%
Net income-$33.9M-39.2%
EPS (diluted)-$0.59-11.3%

Balance sheet

See full
Cash & equivalents$105.4M+266%
Total debt$14.8M+1,083%
Total equity$278.7M+118%
Total assets$326.3M+112%

Cash flow

See full
Operating cash flow-$29.3M-355%
CapEx$5.1M+472%
Free cash flow-$34.4M-369%

Valuation

See full
Market cap$236.86M-42.9%
Enterprise value$146.22M-62.7%

Profitability

See full
Operating margin-778.8%-1,038pp
Net margin-736.6%-981pp
FCF margin-563.9%-954pp

Returns & leverage

See full
Return on equity-56.4%-11.3pp
Debt / equity0.1×0.0×
Current ratio8.4×+1.9×

Where this comes from

Reported directly by Capricor Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 5:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-060382
Line itemThree months ended March 31, 2026Three months ended March 31, 2025
Net cash provided by (used in) investing activities(154,641,596)23,890,673
Cash flows from financing activities:
Proceeds from exercise of stock options1,470,65950,354
Net cash provided by financing activities1,470,65950,354
Net increase (decrease) in cash and cash equivalents(182,425,828)17,507,507
Cash and cash equivalents balance at beginning of period287,847,31211,286,996
Cash and cash equivalents balance at end of period$105,421,484$28,794,503
Supplemental disclosures of cash flow information:

Item 1. Financial Statements.

FAQ

What is Capricor Therapeutics's financing cash flow?
Capricor Therapeutics (CAPR) reported financing cash flow of $1.47M in Q1 2026.
How has Capricor Therapeutics's financing cash flow changed year-over-year?
Capricor Therapeutics's financing cash flow increased by 2820.6% year-over-year, from $50.35K to $1.47M.
What is the long-term trend for Capricor Therapeutics's financing cash flow?
Over 4 years (2021 to 2025), Capricor Therapeutics's financing cash flow has grown at a 87.3% compound annual growth rate (CAGR), from $20.23M to $248.89M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Capricor Therapeutics's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude